Prognostic Significance of CD30 and PDL1 Expression in Patients with MF in Early-Stage Disease
Carlos Neira de Paz, M Carmen Gonzalez-Vela, Marcos A Gonzalez-Lopez, Santiago Montes, Miguel A Piris. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background: Mycosis fungoides (MF) is a non-Hodgkin's T-cell lymphoma of the skin that often begins as limited patches and plaques with slow progression to systemic involvement. We objective was evaluated the prognostic value of CD30 and PDL1 in patients with MF in early-stage disease.
Design: We have analyzed 33 mycosis fungoides (MF) presented with early-stage disease IA-IB. All the cases were retrospectively evaluated analysing their histological and clinical data. Immunohistochemistry was performed in tissues fixed in buffered formalin and embedded in paraffin. The following antibodies were used : CD20, CD3, CD4, CD8, CD30, PDL1.
Results: Disease progression (lymph node y/o bone marrow) occurred only in 18,2%, of cases and 6,3% of patients died due to MF/SS. The mean age at diagnosis was 60,18 years. There were 45% of cases with recurrence after of treatment (corticosteroid and phototherapy) and 69,7% achieved a complete clinical response, with a following up of 34,16 months of mean. We found small-medium –sized lymphocytes CD30 positive (<25%) in 5 of 33 cases. Twenty-nine (87,9%) from 33 cases showed immunoreactivity for PD1L and there were 4 cases with loss of expression for PDL1. We observed that 50% (3) of the cases that showed systemic involvement were negative for PDL1. While that only a 4,34% of the cases positives for PDL1 showed systemic progression (p:0,018).We also observed a relation between the presence of cells CD30 and the systemic involvement (p:0,04). There was no statistically significative relation between the loss of reactivity for PD1L with the recurrence or completed clinical response.
Conclusions: The loss of expression for PDL1 and the presence of CD30 positive cells could be considered parameters associated with poor prognosis in MF in early-stage.
Tuesday, March 20, 2012 9:30 AM
Poster Session III # 103, Tuesday Morning